Pembrolizumab approved in US for first line use in locally advanced or metastatic oesophageal or gastroesophageal junction carcinomas regardless of PD-L1 expression
Approval was based on data from the Phase III KEYNOTE-590 trial of 749 patients which found the combination of pembrolizumab with fluorouracil and cisplatin reduced the risk of death by 27% as compared to cisplatin alone.
Source:
Biospace Inc.